It has been also shown that combination of PD-1 and CTLA-4 blockade directly triggers a Th1-like response that activates the tumor-infiltrating CD103+ DCs (54), which are highly efficient at presenting tumor antigens and show enhanced IL-12 production. The gene discussed is PDCD1; the disease is neoplasm.